Investigational Drug Information for Misonidazole
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug Misonidazole?
Misonidazole is an investigational drug.
There have been 15 clinical trials for Misonidazole.
The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2012.
The most common disease conditions in clinical trials are Hypoxia, Glioblastoma, and Lung Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), Proacta, Incorporated, and Fundación DISA, Canary Islands, Spain.
Summary for Misonidazole
US Patents | 0 |
International Patents | 0 |
US Patent Applications | 2,823 |
WIPO Patent Applications | 1,178 |
Japanese Patent Applications | 596 |
Clinical Trial Progress | Phase 2 (2012-06-01) |
Vendors | 29 |
Recent Clinical Trials for Misonidazole
Title | Sponsor | Phase |
---|---|---|
Tumor Hypoxia and Proliferation in Patients With High-Grade Glioma | William Rhodes Center for Glioblastoma | Phase 1 |
Tumor Hypoxia and Proliferation in Patients With High-Grade Glioma | Weill Medical College of Cornell University | Phase 1 |
Feasibility of FMISO in Brain Tumors | National Cancer Institute (NCI) | Phase 2 |
Clinical Trial Summary for Misonidazole
Top disease conditions for Misonidazole
Top clinical trial sponsors for Misonidazole
US Patents for Misonidazole
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |